COVID-19 and Obstructive Lung Disease: Are COPD and Asthma Risk Factors for Severe COVID-19? Evaluating the Data from the Largest Health System in New York State

Jasmine Schwartz, B. Birnbaum, M. Ballenberger, Omar Mahmoud, B. Mina
{"title":"COVID-19 and Obstructive Lung Disease: Are COPD and Asthma Risk Factors for Severe COVID-19? Evaluating the Data from the Largest Health System in New York State","authors":"Jasmine Schwartz, B. Birnbaum, M. Ballenberger, Omar Mahmoud, B. Mina","doi":"10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1276","DOIUrl":null,"url":null,"abstract":"RATIONALE: An analysis of data collected between March 1, 2020 through July 1, 2020 from the largest health system in New York sought to investigate the association between COVID-19 and obstructive lung disease including asthma and chronic obstructive pulmonary disease (COPD). Methods: A total of 21,865 patients were included in the analysis, 2,518 had obstructive lung disease and COVID-19. There were 1,370 [HA1] patients who had asthma and COVID-19, and 847 patients had COPD and COVID-19. There were 301 patients who had overlapping asthma and COPD diagnoses. There were 19,347 patients who had a diagnosis of COVID-19 without asthma or COPD. Logistic regression analysis of the data was performed. Results: Analysis of our data showed COPD patients with COVID-19 were more likely to be intubated as compared to the control group (OR 1.346 95% CI 1.061-1.707 p=0.0095). Additionally, there was no association between COPD and mortality in patients with COVID-19 (OR 0.845, 95% CI: 0.685-1.042 p=0.1436). There was no association between asthma and COVID-19 and intubation (OR 1.175 95% CI 0.936-1.475 p=0.2193). There was no statistical association between asthma and mortality in patients with COVID-19 (OR 0.849 95% CI 0.669-1.079 p=0.2455). However, patients with asthma were at a decreased risk of dying from COVID-19 compared to COPD patients with COVID-19 even after controlling for comorbid conditions (OR 0.718, 95% CI 0.526-0.979 p=0.0329). Patients presenting with asthma exacerbation or COPD exacerbation in the setting of COVID-19 infection were not at increased risk of death as compared to COPD or asthma patients with COVID-19 (Asthma exacerbation OR 1.042, 95% CI 0.62-1.73 p=0.8796), (COPD exacerbation OR 0.95 95% CI 0.67-1.36 p=0.762). Conclusion: Our finding with regards to intubation may be explained by an aggressive approach early on in the pandemic towards intubation especially in patients that may have been perceived as high-risk patients' due to underlying lung disease. Our data also showed no association between COPD and death in COVID-19 and asthma and mortality in COVID-19-meaning COPD and Asthma were not risk factors for death in our patient population. As to why asthma patients were at decreased odds of dying compared to COPD patients may be related to the different pathophysiological mechanisms of asthma as compared to COPD or a small protective effect of inhaled corticosteroids. Lastly, presenting with an asthma exacerbation or COPD exacerbation in the setting of COVID-19 infection did not increase your odds of mortality.","PeriodicalId":320542,"journal":{"name":"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/AJRCCM-CONFERENCE.2021.203.1_MEETINGABSTRACTS.A1276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

RATIONALE: An analysis of data collected between March 1, 2020 through July 1, 2020 from the largest health system in New York sought to investigate the association between COVID-19 and obstructive lung disease including asthma and chronic obstructive pulmonary disease (COPD). Methods: A total of 21,865 patients were included in the analysis, 2,518 had obstructive lung disease and COVID-19. There were 1,370 [HA1] patients who had asthma and COVID-19, and 847 patients had COPD and COVID-19. There were 301 patients who had overlapping asthma and COPD diagnoses. There were 19,347 patients who had a diagnosis of COVID-19 without asthma or COPD. Logistic regression analysis of the data was performed. Results: Analysis of our data showed COPD patients with COVID-19 were more likely to be intubated as compared to the control group (OR 1.346 95% CI 1.061-1.707 p=0.0095). Additionally, there was no association between COPD and mortality in patients with COVID-19 (OR 0.845, 95% CI: 0.685-1.042 p=0.1436). There was no association between asthma and COVID-19 and intubation (OR 1.175 95% CI 0.936-1.475 p=0.2193). There was no statistical association between asthma and mortality in patients with COVID-19 (OR 0.849 95% CI 0.669-1.079 p=0.2455). However, patients with asthma were at a decreased risk of dying from COVID-19 compared to COPD patients with COVID-19 even after controlling for comorbid conditions (OR 0.718, 95% CI 0.526-0.979 p=0.0329). Patients presenting with asthma exacerbation or COPD exacerbation in the setting of COVID-19 infection were not at increased risk of death as compared to COPD or asthma patients with COVID-19 (Asthma exacerbation OR 1.042, 95% CI 0.62-1.73 p=0.8796), (COPD exacerbation OR 0.95 95% CI 0.67-1.36 p=0.762). Conclusion: Our finding with regards to intubation may be explained by an aggressive approach early on in the pandemic towards intubation especially in patients that may have been perceived as high-risk patients' due to underlying lung disease. Our data also showed no association between COPD and death in COVID-19 and asthma and mortality in COVID-19-meaning COPD and Asthma were not risk factors for death in our patient population. As to why asthma patients were at decreased odds of dying compared to COPD patients may be related to the different pathophysiological mechanisms of asthma as compared to COPD or a small protective effect of inhaled corticosteroids. Lastly, presenting with an asthma exacerbation or COPD exacerbation in the setting of COVID-19 infection did not increase your odds of mortality.
COVID-19和阻塞性肺疾病:COPD和哮喘是重症COVID-19的危险因素吗?评估纽约州最大的卫生系统的数据
理由:对2020年3月1日至2020年7月1日期间从纽约最大的卫生系统收集的数据进行分析,旨在调查COVID-19与包括哮喘和慢性阻塞性肺疾病(COPD)在内的阻塞性肺疾病之间的关系。方法:共纳入21865例患者,其中2518例合并阻塞性肺疾病和COVID-19。哮喘合并COVID-19患者1370例[HA1], COPD合并COVID-19患者847例。有301名患者有重叠的哮喘和COPD诊断。有19347名患者被诊断为COVID-19,但没有哮喘或COPD。对数据进行Logistic回归分析。结果:我们的数据分析显示,与对照组相比,COPD合并COVID-19患者更有可能插管(OR 1.346 95% CI 1.061-1.707 p=0.0095)。此外,COVID-19患者的COPD和死亡率之间没有相关性(OR 0.845, 95% CI: 0.685-1.042 p=0.1436)。哮喘与COVID-19和插管无相关性(OR 1.175 95% CI 0.936-1.475 p=0.2193)。COVID-19患者哮喘与死亡率无统计学相关性(OR 0.849 95% CI 0.669-1.079 p=0.2455)。然而,与合并COVID-19的COPD患者相比,哮喘患者死于COVID-19的风险较低,即使在控制了共病条件后(OR 0.718, 95% CI 0.526-0.979 p=0.0329)。与合并COVID-19的COPD或哮喘患者相比,在COVID-19感染情况下出现哮喘加重或COPD加重的患者的死亡风险没有增加(哮喘加重or 1.042, 95% CI 0.62-1.73 p=0.8796), (COPD加重or 0.95 95% CI 0.67-1.36 p=0.762)。结论:我们在插管方面的发现可能是由于在大流行早期对插管采取了积极的方法,特别是在可能因潜在肺部疾病而被视为高危患者的患者中。我们的数据还显示,COVID-19患者的COPD与死亡、哮喘和死亡率之间没有关联,这意味着COPD和哮喘不是我们患者群体中死亡的危险因素。至于为什么哮喘患者的死亡率比COPD患者低,可能与哮喘与COPD的不同病理生理机制或吸入皮质类固醇的小保护作用有关。最后,在COVID-19感染的情况下出现哮喘加重或COPD加重并不会增加你的死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信